Get started
Beam Therapeutics Inc.Beam Therapeutics Inc.Beam Therapeutics Inc.

Beam Therapeutics Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

BEAM chart


Full chart

BEAM upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.68 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.72 USD
Net income (FY)
‪−132.53 M‬ USD
Revenue (FY)
‪377.71 M‬ USD
Shares float
‪72.59 M‬
Beta (1Y)
1.83

Employees


Employees (FY)
436
Change (1Y)
−71 −14.00%
Revenue / Employee (1Y)
‪866.31 K‬ USD
Net income / Employee (1Y)
‪−303.96 K‬ USD

About Beam Therapeutics Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
John Evans
Website
beamtx.com
Headquarters
Cambridge
Founded
2017
FIGI
BBG00KXC8646
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

BEAM news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of BEAM is 32.40 USD — it has increased by 13.25% in the past 24 hours. Watch Beam Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Beam Therapeutics Inc. stocks are traded under the ticker BEAM.
BEAM stock has risen by 17.65% compared to the previous week, the month change is a 31.49% rise, over the last year Beam Therapeutics Inc. has showed a 1.54% increase.
We've gathered analysts' opinions on Beam Therapeutics Inc. future price: according to them, BEAM price has a max estimate of 80.00 USD and a min estimate of 23.00 USD. Watch BEAM chart and read a more detailed Beam Therapeutics Inc. stock forecast: see what analysts think of Beam Therapeutics Inc. and suggest that you do with its stocks.
BEAM reached its all-time high on Jul 2, 2021 with the price of 138.52 USD, and its all-time low was 13.00 USD and was reached on Mar 16, 2020. View more price dynamics on BEAM chart.
See other stocks reaching their highest and lowest prices.
BEAM stock is 20.39% volatile and has beta coefficient of 1.83. Track Beam Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Beam Therapeutics Inc. there?
Today Beam Therapeutics Inc. has the market capitalization of ‪2.68 B‬, it has decreased by −3.49% over the last week.
Yes, you can track Beam Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Beam Therapeutics Inc. is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
BEAM earnings for the last quarter are −1.17 USD per share, whereas the estimation was −1.18 USD resulting in a 1.12% surprise. The estimated earnings for the next quarter are −1.23 USD per share. See more details about Beam Therapeutics Inc. earnings.
Beam Therapeutics Inc. revenue for the last quarter amounts to ‪14.27 M‬ USD, despite the estimated figure of ‪14.52 M‬ USD. In the next quarter, revenue is expected to reach ‪17.17 M‬ USD.
BEAM net income for the last quarter is ‪−96.67 M‬ USD, while the quarter before that showed ‪−91.05 M‬ USD of net income which accounts for −6.17% change. Track more Beam Therapeutics Inc. financial stats to get the full picture.
No, BEAM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 16, 2025, the company has 436.00 employees. See our rating of the largest employees — is Beam Therapeutics Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Beam Therapeutics Inc. EBITDA is ‪−160.83 M‬ USD, and current EBITDA margin is −41.43%. See more stats in Beam Therapeutics Inc. financial statements.
Like other stocks, BEAM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Beam Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Beam Therapeutics Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Beam Therapeutics Inc. stock shows the buy signal. See more of Beam Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.